Genexine Stock | 095700.KQ | KR7095700001 |

Date	Genexine Price
10/4/2024	6,200.00 undefined
10/2/2024	6,080.00 undefined
9/30/2024	6,160.00 undefined
9/27/2024	6,300.00 undefined
9/26/2024	6,380.00 undefined
9/25/2024	6,310.00 undefined
9/24/2024	6,360.00 undefined
9/23/2024	6,330.00 undefined
9/20/2024	6,370.00 undefined
9/19/2024	6,290.00 undefined
9/13/2024	6,140.00 undefined
9/12/2024	6,280.00 undefined
9/11/2024	6,210.00 undefined
9/10/2024	6,200.00 undefined
9/9/2024	6,260.00 undefined
9/6/2024	6,080.00 undefined

Date	Genexine Revenue	Genexine EBIT	Genexine Net Income
2026e	41.41 B undefined	-1.8 T undefined	-2.12 T undefined
2025e	21.21 B undefined	-909 B undefined	-1.07 T undefined
2024e	10.1 B undefined	-52.52 B undefined	-44.63 B undefined
2023	4.43 B undefined	-41.24 B undefined	-66.87 B undefined
2022	16.14 B undefined	-33.68 B undefined	-55.97 B undefined
2021	36.83 B undefined	-19.37 B undefined	-48.04 B undefined
2020	18.54 B undefined	-39.16 B undefined	27.57 B undefined
2019	11.3 B undefined	-44.54 B undefined	-16.51 B undefined
2018	12.88 B undefined	-38.08 B undefined	-34.07 B undefined
2017	28.46 B undefined	-26.86 B undefined	-19.33 B undefined
2016	11.35 B undefined	-30.89 B undefined	-30.93 B undefined
2015	32.52 B undefined	1.09 B undefined	-1.43 B undefined
2014	16.66 B undefined	-5.21 B undefined	-7.41 B undefined
2013	5.76 B undefined	-7.05 B undefined	-9 B undefined
2012	6.25 B undefined	-2.69 B undefined	-2.1 B undefined
2011	2.66 B undefined	-6.29 B undefined	-7.05 B undefined
2010	1.08 B undefined	-5.42 B undefined	-4.71 B undefined
2009	1.07 B undefined	-492 M undefined	-494 M undefined
2008	1.24 B undefined	-387 M undefined	-608 M undefined
2007	1.21 B undefined	-110 M undefined	-187 M undefined
2006	897 M undefined	145 M undefined	305 M undefined
2005	167 M undefined	26 M undefined	43 M undefined
2004	147 M undefined	-41 M undefined	-32 M undefined

	Revenue	EBIT	Net Income
2004	147 M KRW	-41 M KRW	-32 M KRW
2005	167 M KRW	26 M KRW	43 M KRW
2006	897 M KRW	145 M KRW	305 M KRW
2007	1.21 B KRW	-110 M KRW	-187 M KRW
2008	1.24 B KRW	-387 M KRW	-608 M KRW
2009	1.07 B KRW	-492 M KRW	-494 M KRW
2010	1.08 B KRW	-5.42 B KRW	-4.71 B KRW
2011	2.66 B KRW	-6.29 B KRW	-7.05 B KRW
2012	6.25 B KRW	-2.69 B KRW	-2.1 B KRW
2013	5.76 B KRW	-7.05 B KRW	-9 B KRW
2014	16.66 B KRW	-5.21 B KRW	-7.41 B KRW
2015	32.52 B KRW	1.09 B KRW	-1.43 B KRW
2016	11.35 B KRW	-30.89 B KRW	-30.93 B KRW
2017	28.46 B KRW	-26.86 B KRW	-19.33 B KRW
2018	12.88 B KRW	-38.08 B KRW	-34.07 B KRW
2019	11.3 B KRW	-44.54 B KRW	-16.51 B KRW
2020	18.54 B KRW	-39.16 B KRW	27.57 B KRW
2021	36.83 B KRW	-19.37 B KRW	-48.04 B KRW
2022	16.14 B KRW	-33.68 B KRW	-55.97 B KRW
2023	4.43 B KRW	-41.24 B KRW	-66.87 B KRW
2024e	10.1 B KRW	-52.52 B KRW	-44.63 B KRW
2025e	21.21 B KRW	-909 B KRW	-1.07 T KRW
2026e	41.41 B KRW	-1.8 T KRW	-2.12 T KRW

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022

0.14	1.7	0.8	3.34	1.9	26.2	17.2	11.84	20.46	3.21	46.43	20.58	59.28	10.43	171	82.52	6.71	27.8	21.94
0.01	0.02	0.33	1.14	0.67	0.3	0.71	0.37	0.14	3.23	2.76	21.15	5.6	14.67	2.49	3.35	2.74	1.12	12.22
0	0	0.01	0.01	0.02	0.02	0.15	1.74	0.12	1.55	1.71	0.35	1.02	0.48	0.33	0.97	5.61	1.32	1.56
0	0	0	0	0	0	0	0	0	0.15	0.11	0.19	0.13	0	0	0	0	7.17	12.03
0	0	0.41	0.92	0.78	1.47	1.04	0.34	0.35	0.8	0.69	1.15	5.83	3.31	3.7	8.98	5.59	19.87	4.64
0.15	1.72	1.55	5.41	3.36	28	19.09	14.29	21.07	8.93	51.7	43.42	71.86	28.89	177.52	95.82	20.65	57.27	52.38
0.01	0.14	0.42	2.47	4.42	5.2	13.13	18.51	19.79	19.86	23.82	24.35	23.6	41.3	47.18	49.84	71.86	111.97	110.93
0	0.44	0	0	0	0	1.59	1.22	11.81	11.75	15.71	33.33	54.49	63.48	144.05	206.64	497.64	461.36	220.14
0	0	0	0	10	10	0	0	0	0	0	480	0	0	0	0	0	0	0
2.79	2.94	3.9	5.18	6.64	8.25	0.96	0.57	6.3	11.2	20.65	35.68	44.82	4.19	4.1	4.6	4.07	3.28	2.05
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.06	0.07	0.15	0.44	0.34	1.33	2.91	4.6	4.41	4.11	2.23	4.85	3.94	2.88	1.97	1.29	2.7	2.98	3.27
2.86	3.59	4.46	8.09	11.41	14.79	18.58	24.9	42.31	46.92	62.41	98.68	126.85	111.84	197.29	262.36	576.26	579.59	336.4
3	5.31	6.01	13.49	14.77	42.78	37.67	39.19	63.38	55.85	114.11	142.1	198.71	140.73	374.81	358.18	596.91	636.86	388.78

2.2	1.45	1.45	1.45	1.53	2.31	2.32	2.52	3.11	3.14	4.27	4.52	9.73	10.03	11.32	11.88	12.35	12.51	12.57
0.34	3.19	3.19	3.2	5.09	36.55	36.71	41.55	64.98	66.19	133.61	158.36	219.53	221.44	452.88	457.53	551.13	562.72	565.16
315	358	662	476	-397	-890	-13,491	-20,850	-23,363	-32,483	-40,004	-41,702	-66,409	-125,724	-160,141	-176,851	-153,960	-164,267.25	-231,597.73
0	0	0.24	0.59	0.54	0.54	0.67	0.98	1.19	1.39	3.19	6.82	10.86	12.39	12.75	14.72	16.7	15.77	18.41
0	0	0	0	0	0	0.23	0	-0.09	0.07	-0.14	-2.23	-3.47	-4.23	3.69	-10.36	109.39	91.01	-88.39
2.85	5	5.54	5.72	6.76	38.5	26.43	24.2	45.83	38.3	100.93	125.77	170.24	113.91	320.51	296.91	535.61	517.74	276.15
0	0	0	0	0	0	0	3	0	4	20	13	0	0	0	0	0	0	0
0	0.01	0.03	0.07	0.08	0.02	0.13	0.39	0.33	0.39	0.49	0.18	0.61	0.45	1.38	1.83	2.58	1.69	1.23
0	0.15	0.17	0.06	0.06	0.16	2.06	1.92	2.99	1.95	3.79	11.54	5.44	8.67	9.44	10.64	26.45	46.04	12.27
0	0	0	0.1	0	0	0.99	10.38	3	3	0	0	0	3	0	0	10	10	51.64
0	0	0	0	0	0	0	0	0	10.35	3	3	20.01	0.83	0	10.16	1.19	1.43	13.79
0	0.16	0.2	0.23	0.14	0.17	3.17	12.7	6.32	15.7	7.3	14.73	26.06	12.95	10.83	22.64	40.22	59.15	78.93
0	0	0	7.01	6.9	2.43	6.9	0.1	9.31	0	4.26	0	0	11.46	34.61	29.21	15.96	40.79	18.65
146	112	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.04	0.27	0.53	0.97	1.68	1.18	2.35	1.92	1.85	1.62	1.61	2.41	2.42	8.87	9.42	4.19	13.65	10.29
0.15	0.15	0.28	7.55	7.87	4.11	8.07	2.45	11.23	1.85	5.88	1.61	2.41	13.87	43.48	38.63	20.16	54.44	28.94
0.15	0.32	0.47	7.78	8.01	4.28	11.24	15.15	17.55	17.54	13.18	16.33	28.47	26.82	54.3	61.27	60.38	113.59	107.87
3	5.31	6.01	13.5	14.77	42.78	37.67	39.34	63.38	55.85	114.11	142.1	198.71	140.73	374.81	358.18	595.98	631.33	384.03

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-0.03	0.04	0.3	-0.19	-0.61	-0.49	-4.71	-7.05	-2.1	-9	-7.41	-1.43	-30.93	-19.33	-34.07	-16.51	27.54	0	0	-66.86
0.01	0.01	0.12	0.14	0.2	0.21	0.37	0.73	3.43	4.44	6.56	3.61	2.55	2.65	2.28	2.5	2.92	3.3	4.81	4.97
-7	-3	-105	-26	-6	-5	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-0.03	0.01	-0.7	-1.28	0.68	-0.3	0.1	1.75	0.08	-5.58	1.69	-12.68	7.36	-5.7	11.39	-5.15	9.11	-1.47	-18.33	6.03
0.01	0	0.24	0.61	0.72	0.63	-0.38	1.1	0.25	3.44	5.63	8.86	6.93	-3.73	0.34	-22.41	-62.26	33.99	30.85	17.81
0	0	0	0	0	0	0.18	0.46	0.45	0.84	0.39	0.12	0.26	0.5	0.33	0.25	0.15	0.49	1.3	2.43
0	0	0	0	0	0	0	0	-33	-43	-38	-16	-73	-62	-61	-246	-356	-166	9	307
-0.05	0.07	-0.14	-0.74	0.98	0.04	-4.62	-3.48	1.67	-6.7	6.47	-1.64	-14.1	-26.1	-20.05	-41.57	-22.69	-12.75	-39.8	-38.05
-152	-234	-1,741	-3,299	-4,178	-4,138	-10,726	-5,703	-10,646	-9,588	-20,060	-20,288	-5,065	-20,505	-8,009	-5,081	-24,116	-57,006	-31,779	-7,378
0	-1.66	-0.56	-6.14	-2.47	-28.17	-3.24	-2.45	-26.93	4.89	-25.54	-54.82	-53.65	17.77	-185.62	1.64	-64.39	-7.7	-1.92	-34.28
0.16	-1.42	1.18	-2.84	1.71	-24.03	7.49	3.26	-16.28	14.48	-5.48	-34.54	-48.58	38.28	-177.61	6.72	-40.28	49.3	29.86	-26.9
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-0	0	5.7	-0.1	1.28	5.46	2.5	9.27	0	7	0	19.71	-7.7	44.71	-0.17	11.5	23.17	29.66	-10.68
0.01	2.1	0	0	1.18	25.94	0.09	5.03	16.42	0.93	54.36	20.41	61.39	4.06	206.22	3.5	61.86	13.45	1.98	84.22
0.01	2.17	0.59	6.73	1.71	30.06	8.24	7.53	25.76	0.57	60.98	20.41	81.1	-3.64	250.93	3.33	73.36	43.09	31.63	60.43
0	0.07	0.59	1.03	0.63	2.84	2.7	0	0.08	-0.36	-0.39	0	0	0	0	0	0	6.47	0	-13.12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-0.04	0.58	-0.1	-0.16	0.22	1.92	0.39	1.61	0.48	-1.25	41.9	-36.05	13.35	-11.97	45.25	-36.63	-13.88	22.58	-9.85	-11.91
-205.8	-168.8	-1,878.5	-4,041.5	-3,199.9	-4,102.9	-15,342.1	-9,181.3	-8,978.2	-16,286.1	-13,593.8	-21,931.1	-19,164.7	-46,610.3	-28,063.8	-46,653.5	-46,807.3	-69,752.24	-71,578.7	-45,433.25
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Genexine Gross margin	Genexine Profit margin	Genexine EBIT margin	Genexine Profit margin
2026e	8.75 %	-4,358.54 %	-5,112.07 %
2025e	8.75 %	-4,285.71 %	-5,032.65 %
2024e	8.75 %	-520 %	-441.86 %
2023	8.75 %	-931.65 %	-1,510.71 %
2022	70.41 %	-208.68 %	-346.82 %
2021	86.36 %	-52.6 %	-130.45 %
2020	62.97 %	-211.18 %	148.68 %
2019	65.94 %	-394.02 %	-146.06 %
2018	50.88 %	-295.63 %	-264.45 %
2017	62.42 %	-94.39 %	-67.93 %
2016	57.9 %	-272.08 %	-272.49 %
2015	84.94 %	3.34 %	-4.39 %
2014	79.65 %	-31.26 %	-44.51 %
2013	65.3 %	-122.5 %	-156.37 %
2012	89.57 %	-43.07 %	-33.53 %
2011	89.06 %	-236.41 %	-265.09 %
2010	81.46 %	-502.13 %	-436.33 %
2009	87.75 %	-46.02 %	-46.21 %
2008	90.87 %	-31.29 %	-49.15 %
2007	8.75 %	-9.1 %	-15.47 %
2006	97.55 %	16.16 %	34 %
2005	86.83 %	15.57 %	25.75 %
2004	61.22 %	-27.89 %	-21.77 %

	Gross margin	EBIT margin	Profit margin
2004	61.22 %	-27.89 %	-21.77 %
2005	86.83 %	15.57 %	25.75 %
2006	97.55 %	16.16 %	34 %
2007	8.75 %	-9.1 %	-15.47 %
2008	90.87 %	-31.29 %	-49.15 %
2009	87.75 %	-46.02 %	-46.21 %
2010	81.46 %	-502.13 %	-436.33 %
2011	89.06 %	-236.41 %	-265.09 %
2012	89.57 %	-43.07 %	-33.53 %
2013	65.3 %	-122.5 %	-156.37 %
2014	79.65 %	-31.26 %	-44.51 %
2015	84.94 %	3.34 %	-4.39 %
2016	57.9 %	-272.08 %	-272.49 %
2017	62.42 %	-94.39 %	-67.93 %
2018	50.88 %	-295.63 %	-264.45 %
2019	65.94 %	-394.02 %	-146.06 %
2020	62.97 %	-211.18 %	148.68 %
2021	86.36 %	-52.6 %	-130.45 %
2022	70.41 %	-208.68 %	-346.82 %
2023	8.75 %	-931.65 %	-1,510.71 %
2024e	8.75 %	-520 %	-441.86 %
2025e	8.75 %	-4,285.71 %	-5,032.65 %
2026e	8.75 %	-4,358.54 %	-5,112.07 %

Date	Genexine Sales per Share	Genexine EBIT per share	Genexine Earnings per Share
2026e	999.04 undefined	0 undefined	-51,071.59 undefined
2025e	511.7 undefined	0 undefined	-25,752.23 undefined
2024e	243.67 undefined	0 undefined	-1,076.67 undefined
2023	109.36 undefined	-1,018.87 undefined	-1,652.14 undefined
2022	494.45 undefined	-1,031.83 undefined	-1,714.88 undefined
2021	1,061.46 undefined	-558.37 undefined	-1,384.65 undefined
2020	772.63 undefined	-1,631.63 undefined	1,148.75 undefined
2019	538.24 undefined	-2,120.76 undefined	-786.14 undefined
2018	644.1 undefined	-1,904.15 undefined	-1,703.35 undefined
2017	1,580.83 undefined	-1,492.17 undefined	-1,073.89 undefined
2016	709.5 undefined	-1,930.38 undefined	-1,933.31 undefined
2015	2,168 undefined	72.4 undefined	-95.13 undefined
2014	1,189.71 undefined	-371.93 undefined	-529.5 undefined
2013	479.58 undefined	-587.5 undefined	-749.92 undefined
2012	625.2 undefined	-269.3 undefined	-209.6 undefined
2011	295.67 undefined	-699 undefined	-783.78 undefined
2010	119.89 undefined	-602 undefined	-523.11 undefined
2009	152.71 undefined	-70.29 undefined	-70.57 undefined
2008	206.17 undefined	-64.5 undefined	-101.33 undefined
2007	201.5 undefined	-18.33 undefined	-31.17 undefined
2006	149.5 undefined	24.17 undefined	50.83 undefined
2005	33.4 undefined	5.2 undefined	8.6 undefined
2004	36.75 undefined	-10.25 undefined	-8 undefined

	Sales per Share	EBIT per share	Earnings per Share
2004	36.75 KRW	-10.25 KRW	-8 KRW
2005	33.4 KRW	5.2 KRW	8.6 KRW
2006	149.5 KRW	24.17 KRW	50.83 KRW
2007	201.5 KRW	-18.33 KRW	-31.17 KRW
2008	206.17 KRW	-64.5 KRW	-101.33 KRW
2009	152.71 KRW	-70.29 KRW	-70.57 KRW
2010	119.89 KRW	-602 KRW	-523.11 KRW
2011	295.67 KRW	-699 KRW	-783.78 KRW
2012	625.2 KRW	-269.3 KRW	-209.6 KRW
2013	479.58 KRW	-587.5 KRW	-749.92 KRW
2014	1,189.71 KRW	-371.93 KRW	-529.5 KRW
2015	2,168 KRW	72.4 KRW	-95.13 KRW
2016	709.5 KRW	-1,930.38 KRW	-1,933.31 KRW
2017	1,580.83 KRW	-1,492.17 KRW	-1,073.89 KRW
2018	644.1 KRW	-1,904.15 KRW	-1,703.35 KRW
2019	538.24 KRW	-2,120.76 KRW	-786.14 KRW
2020	772.63 KRW	-1,631.63 KRW	1,148.75 KRW
2021	1,061.46 KRW	-558.37 KRW	-1,384.65 KRW
2022	494.45 KRW	-1,031.83 KRW	-1,714.88 KRW
2023	109.36 KRW	-1,018.87 KRW	-1,652.14 KRW
2024e	243.67 KRW	0 KRW	-1,076.67 KRW
2025e	511.7 KRW	0 KRW	-25,752.23 KRW
2026e	999.04 KRW	0 KRW	-51,071.59 KRW

	Number of stocks
2004	4 M Aktien
2005	5 M Aktien
2006	6 M Aktien
2007	6 M Aktien
2008	6 M Aktien
2009	7 M Aktien
2010	9 M Aktien
2011	9 M Aktien
2012	10 M Aktien
2013	12 M Aktien
2014	14 M Aktien
2015	15 M Aktien
2016	16 M Aktien
2017	18 M Aktien
2018	20 M Aktien
2019	21 M Aktien
2020	24 M Aktien
2021	34.7 M Aktien
2022	32.64 M Aktien
2023	40.48 M Aktien
2024e	40.48 M Aktien
2025e	40.48 M Aktien
2026e	40.48 M Aktien

Date	EPS Estimate	EPS Actual	Quarterly report
12/31/2023	-229.25	76 (133.15 %)	2023 Q4
9/30/2023	-386.72	-504 (-30.33 %)	2023 Q3
6/30/2023	-470.95	-603 (-28.04 %)	2023 Q2
3/31/2023	494.39	-665 (-234.51 %)	2023 Q1
12/31/2022	-996.84	-1,539 (-54.39 %)	2022 Q4
9/30/2022	-150.88	-574.62 (-280.84 %)	2022 Q3
6/30/2022	-180.18	-439.46 (-143.9 %)	2022 Q2
12/31/2020	-608.21	593.92 (197.65 %)	2020 Q4
9/30/2020	-351.85	1,044.55 (396.87 %)	2020 Q3
6/30/2020	-447.11	-297.9 (33.37 %)	2020 Q2
3/31/2020	-511.44	-592.04 (-15.76 %)	2020 Q1
12/31/2019	-122.89	-639.93 (-420.75 %)	2019 Q4
9/30/2019	-369.25	-404.43 (-9.53 %)	2019 Q3
6/30/2019	-664.24	-983.27 (-48.03 %)	2019 Q2
3/31/2019	-424.09	1,202.92 (383.65 %)	2019 Q1
12/31/2018	-104.13	-85.79 (17.62 %)	2018 Q4
9/30/2018	-191.38	-761.73 (-298.01 %)	2018 Q3
6/30/2018	-39.99	-210.23 (-425.7 %)	2018 Q2

%	Name	Stocks	Change	Date
5.87500 %	Seong (Yeong Cheol)	2,435,174	0	12/31/2023
2.27790 %	The Vanguard Group, Inc.	944,185	-40,556	3/31/2024
14.59244 %	Handok Inc	6,048,534	0	12/31/2023
1.22651 %	Samsung Asset Management Co., Ltd.	508,384	-2,024	2/29/2024
0.64776 %	Dimensional Fund Advisors, L.P.	268,496	191	2/29/2024
0.37735 %	Mirae Asset Global Investments Co., Ltd.	156,409	7,059	1/31/2024
0.20389 %	KB Asset Management Co., Ltd.	84,513	18,601	2/29/2024
0.19863 %	Norges Bank Investment Management (NBIM)	82,333	-212,872	12/31/2023
0.14030 %	Charles Schwab Investment Management, Inc.	58,156	0	3/31/2024
0.10260 %	Dimensional Fund Advisors, Ltd.	42,526	3,618	2/29/2024
0.10155 %	State Street Global Advisors (US)	42,091	388	2/29/2024
0.06273 %	Koreit Asset Management Co., Ltd.	26,000	-6,500	9/30/2023
0.01632 %	Shinhan Asset Management Co Ltd	6,765	-294	9/30/2023
0.01373 %	Korea Investment Management Co., Ltd.	5,690	371	9/30/2023
0.01247 %	NH-Amundi Asset Management Co., Ltd.	5,169	-273	9/30/2023
0.01201 %	Genexine Company Limited Employees	4,978	0	12/31/2023
0.01071 %	Kiwoom Asset Management Co., Ltd.	4,440	-177	2/29/2024
0.00582 %	Invesco Capital Management LLC	2,411	16	3/31/2024
0.00486 %	American Century Investment Management, Inc.	2,013	0	3/31/2024
0.00373 %	Truston Asset Management Co., Ltd.	1,545	0	9/30/2023
0.00348 %	Vanguard Global Advisers LLC	1,442	0	3/31/2024
0.00320 %	Hanwha Asset Management Co., Ltd.	1,325	-252	1/31/2024
0.00089 %	Avantis Investors	369	0	3/31/2024
0 %	DBX Advisors LLC.	0	-3,227	2/28/2023
0 %	Crux Asset Management Limited	0	-14,766	7/31/2023
0 %	DWS Investments UK Limited	0	-997	2/28/2023
0 %	Hyundai Asset Management Co., Ltd.	0	-8,092	9/30/2023
0 %	VI Asset Management Korea Co. Ltd.	0	-440	6/30/2023
0 %	Geode Capital Management, L.L.C.	0	-16,631	9/30/2023
0 %	Warburg Invest AG	0	-179	3/31/2023
0 %	BlackRock Investment Management (Australia) Ltd.	0	-1,099	4/30/2023
0 %	Legal & General Investment Management Ltd.	0	-913	12/31/2022
0 %	Baillie Gifford & Co.	0	-3,844	9/30/2022
0 %	Janus Henderson Investors	0	-1,244	11/30/2022
0 %	HSBC Global Asset Management (UK) Limited	0	-1,358	11/30/2023
0 %	BlackRock Advisors (UK) Limited	0	-2,756	12/31/2023
0 %	Handelsbanken Kapitalförvaltning AB	0	-10,400	11/30/2022
0 %	State Street Global Advisors Ireland Limited	0	-4,386	12/31/2023
0 %	WCM Investment Management	0	-18,123	9/30/2022
0 %	BlackRock Institutional Trust Company, N.A.	0	-43,504	12/31/2023
0 %	Wellington Management Company, LLP	0	-16,390	9/30/2022
0 %	Nuveen LLC	0	-27,627	11/30/2023
0 %	Northern Trust Investments, Inc.	0	-441	12/31/2023
0 %	Parametric Portfolio Associates LLC	0	-3,250	8/31/2022
0 %	Goldman Sachs Asset Management, L.P.	0	-133	11/30/2022
0 %	Mellon Investments Corporation	0	-17,373	10/31/2022
0 %	Welcome Asset Management Corporation	0	-11,861	12/31/2022

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Merck & Co	SupplierCustomer	0,64	-0,31	-0,89	-0,82	-0,55	-
GenNBio	SupplierCustomer	0,53	0,81	0,82	0,82	0,83	-
Binex	SupplierCustomer	0,30	0,77	0,75	-0,06	0,81	-
Ajinomoto	SupplierCustomer	0,20	0,80	0,58	0,42	-0,68	-
NeoImmuneTech KDR	SupplierCustomer	0,11	-	-0,55	0,53	-	-
Shanghai Fosun Pharm H	SupplierCustomer	-0,03	0,31	-0,13	0,28	0,88	-
I-MAB ADR	SupplierCustomer	-0,28	0,63	0,80	0,94	0,92	-
Rezolute	SupplierCustomer	-0,48	0,34	-0,26	0,61	0,94	-
SCM LIFESCIENCE	SupplierCustomer	-0,48	0,14	0,88	0,85	0,86	-
Mirae Asset Venture Investment	SupplierCustomer	-0,74	0,50	0,86	-0,21	-0,19	-

What values and corporate philosophy does Genexine represent?

Genexine Inc represents values of innovation, dedication, and collaboration in the field of biotechnology. The company is committed to developing cutting-edge therapeutics and vaccines to address unmet medical needs. With a focus on research and development, Genexine strives to improve the quality of life for patients worldwide. The company's corporate philosophy emphasizes integrity, transparency, and a patient-centric approach. Genexine Inc aims to create sustainable growth by fostering strong partnerships and expanding its pipeline of innovative drug candidates. With its commitment to scientific advancement and strong corporate values, Genexine Inc is poised to make significant contributions to the biotech industry.

In which countries and regions is Genexine primarily present?

Genexine Inc is primarily present in South Korea, where its headquarters are located.

What significant milestones has the company Genexine achieved?

Genexine Inc has achieved several significant milestones in its history. These include successful completion of clinical trials for their pipeline products, securing strategic partnerships with renowned pharmaceutical companies, and obtaining regulatory approvals for commercialization. Genexine has also received recognition for its innovative research and development efforts, resulting in numerous patent grants. Additionally, the company has successfully raised capital through public offerings and private placements to support its growth strategy and further advance its portfolio. Through these milestones, Genexine Inc has demonstrated its commitment to advancements in the field of biotechnology and its dedication to improving patient outcomes.

What is the history and background of the company Genexine?

Genexine Inc is a reputable biotechnology company with a rich history and background. Established in 1999, Genexine has since emerged as a leading player in the field of genetic medicine. The company specializes in developing innovative and effective therapeutics using its cutting-edge platform technologies. Genexine has successfully advanced several clinical candidates that target various diseases, including cancer, infectious diseases, and immune disorders. With a strong focus on research and development, Genexine has gained recognition for its robust pipeline and collaborations with global pharmaceutical companies. As a result, Genexine Inc has established itself as a trusted name in the biotech industry, dedicated to improving patient lives through advanced medical innovation.

Who are the main competitors of Genexine in the market?

The main competitors of Genexine Inc in the market include other companies operating in the biotechnology and pharmaceutical industries. Some notable competitors include Celltrion Inc, Samsung Biologics, and Hanmi Pharmaceutical Co. These companies also focus on developing and commercializing innovative drugs, therapies, and biologics, which creates a competitive landscape for Genexine Inc in the market.

In which industries is Genexine primarily active?

Genexine Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Genexine?

The business model of Genexine Inc involves the development and commercialization of innovative biopharmaceutical products. Genexine focuses on the research and development of novel immunotherapeutics and long-acting biologics, including therapeutic DNA vaccines and recombinant protein-based drugs. Their goal is to address critical unmet medical needs and provide effective treatment options for patients. By leveraging their expertise in genetic engineering and biotechnology, Genexine aims to contribute to the advancement of healthcare and enhance patients' quality of life through the development of cutting-edge therapeutics.

What is the P/E ratio of Genexine 2024?

The Genexine P/E ratio is -5.62.

What is the P/S ratio of Genexine 2024?

The Genexine P/S ratio is 24.85.

What is the AlleAktien quality score of Genexine?

The AlleAktien quality score for Genexine is 3/10.

What is the revenue of Genexine 2024?

The expected Genexine revenue is 10.1 B KRW.

How high is the profit of Genexine 2024?

The expected Genexine profit is -44.63 B KRW.

What is the business model of Genexine

Genexine Inc is an emerging biotechnology company based in South Korea. Its goal is to develop and market innovative, highly effective therapies for a variety of diseases. The company has a wide portfolio of products and services focused on three main areas: therapeutics, vaccines, and diagnostics. In the therapeutics field, Genexine focuses on the development of biopharmaceuticals that can be used to treat cancer, autoimmune diseases, and other serious conditions. The company has several potential products in the pipeline, including GX-I7, an immunotherapy for the treatment of metastatic breast cancer, and GX-188E, a DNA vaccine for the treatment of HPV-related cervical cancer. Genexine is also involved in the development of vaccines that can be used to combat infectious diseases such as HPV, influenza, and COVID-19. The company has collaborated with other biotech companies and scientists to develop COVID-19 vaccines that are currently undergoing clinical trials. In addition to therapeutics and vaccines, Genexine also offers diagnostic services. The company has a proprietary technology platform called Polyplex, which can be used for the production of DNA and RNA vaccines, as well as disease diagnosis. By utilizing this technology platform, Genexine can perform accurate and rapid diagnoses of infectious diseases and be able to produce tailored vaccines. Genexine also works closely with other biotechnology companies and academic research institutions. For example, the company has announced a collaboration with BioNTech to develop an mRNA vaccine platform for cancer immunotherapy. The company has also signed a cooperation agreement with the Cleveland Clinic to develop new and innovative therapies for the treatment of cancer and autoimmune diseases. In terms of funding, Genexine enters into strategic partnerships to support the development of its products and services. The company has a business partnership with Chinese company Qilu Pharmaceutical to further develop and market its cancer therapeutics GXNPC. Genexine has also made an agreement with Korean company ToolGen to further develop and market its Polyplex technology platform. Overall, Genexine's business model is focused on developing and bringing to market innovative, highly effective products that can contribute to improving the health and well-being of people worldwide. Through collaboration with strategic partners and a commitment to groundbreaking research and development, Genexine aims to become a leading biotechnology company in the coming years.

What is the Genexine dividend?

Genexine pays a dividend of 0 KRW distributed over payouts per year.

How often does Genexine pay dividends?

The dividend cannot currently be calculated for Genexine or the company does not pay out a dividend.

What is the Genexine ISIN?

The ISIN of Genexine is KR7095700001.

What is the Genexine ticker?

The ticker of Genexine is 095700.KQ.

How much dividend does Genexine pay?

Over the past 12 months, Genexine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genexine is expected to pay a dividend of 0 KRW.

What is the dividend yield of Genexine?

The current dividend yield of Genexine is .

When does Genexine pay dividends?

Genexine pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genexine?

Genexine paid dividends every year for the past 0 years.

What is the dividend of Genexine?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genexine located?

Genexine is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genexine kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genexine from 10/5/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did Genexine pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of Genexine in the year 2023?

In the year 2023, Genexine distributed 0 KRW as dividends.

In which currency does Genexine pay out the dividend?

The dividends of Genexine are distributed in KRW.

Genexine Ticker	Genexine FIGI
095700:KS	BBG000NWBQH5
095700:KQ	BBG000NWBRZ3
GNXCF:PQ	BBG00DGPKC36
GNXCF:UV	BBG00DGPKC45

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0.15	0.17	0.9	1.21	1.24	1.07	1.08	2.66	6.25	5.76	16.66	32.52	11.35	28.46	12.88	11.3	18.54	36.83	16.14	4.43	10.1	21.21	41.41
-	13.61	437.13	34.78	2.32	-13.58	0.94	146.62	134.95	-7.95	189.42	95.24	-65.09	150.66	-54.73	-12.26	64.05	98.61	-56.18	-72.58	128.20	110.00	95.24
61.22	86.83	97.55	-	90.86	87.75	81.46	89.06	89.57	65.30	79.65	84.94	57.90	62.42	50.88	65.94	62.97	86.36	70.41	8.74	-	-	-
0.09	0.15	0.88	0	1.12	0.94	0.88	2.37	5.6	3.76	13.27	27.62	6.57	17.76	6.56	7.45	11.68	31.81	11.36	0.39	0	0	0
-0.04	0.03	0.15	-0.11	-0.39	-0.49	-5.42	-6.29	-2.69	-7.05	-5.21	1.09	-30.89	-26.86	-38.08	-44.54	-39.16	-19.37	-33.68	-41.24	-52.52	-909	-1,804.87
-27.89	15.57	16.16	-9.10	-31.29	-46.02	-502.13	-236.41	-43.07	-122.50	-31.26	3.34	-272.08	-94.39	-295.63	-394.02	-211.18	-52.60	-208.68	-931.77	-520.00	-4,285.71	-4,358.54
-0.03	0.04	0.31	-0.19	-0.61	-0.49	-4.71	-7.05	-2.1	-9	-7.41	-1.43	-30.93	-19.33	-34.07	-16.51	27.57	-48.04	-55.97	-66.87	-44.63	-1,067.42	-2,116.91
-	-234.38	609.30	-161.31	225.13	-18.75	853.04	49.83	-70.29	329.34	-17.62	-80.75	2,067.69	-37.51	76.24	-51.54	-267.00	-274.25	16.51	19.47	-33.27	2,291.88	98.32
4	5	6	6	6	7	9	9	10	12	14	15	16	18	20	21	24	34.7	32.64	40.48	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Genexine stock stock price, forecast, news, chart, split, dividend and analysis Genexine ariva, Genexine onvista, Genexine finanzen.net, Genexine aktienfinder, Genexine marketscreener, Genexine marketwatch, Genexine bloomberg, Genexine handelsblatt, Genexine wiwo, Genexine forum

Price

Price

Ticker095700.KQ

ISINKR7095700001

Genexine stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Genexine Stock Price History

Genexine Revenue, EBIT, Net Income KR7095700001 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Genexine Revenue, EBIT and net profit per share

Genexine Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Genexine stock margins KR7095700001 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Genexine Margin History

Genexine Stock Sales Revenue, EBIT, Earnings per Share KR7095700001 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Genexine Revenue, EBIT and net profit per share

Genexine business model

Genexine SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Genexine Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Genexine historical P/E ratio, EBIT multiple, and P/S ratio

Genexine shares outstanding KR7095700001 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Genexine stock splits

Genexine Earnings Estimates

Genexine latest earnings and earnings surprises

Genexine shareholders

Genexine Executives and Management Board

Genexine Supply Chain

Most common questions regarding Genexine

What values and corporate philosophy does Genexine represent?

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Genexine stock
stock price, forecast, news, chart, split, dividend and analysis Genexine ariva, Genexine onvista, Genexine finanzen.net, Genexine aktienfinder, Genexine marketscreener, Genexine marketwatch, Genexine bloomberg, Genexine handelsblatt, Genexine wiwo, Genexine forum

Ticker
095700.KQ

ISIN
KR7095700001